Loading clinical trials...
Loading clinical trials...
Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt.
Conditions
Interventions
LCP-Tacro
Prograf
Locations
1
United States
California Institute of Renal Research/ Sharp Memorial
San Diego, California, United States
Start Date
December 1, 2008
Primary Completion Date
February 1, 2011
Completion Date
February 1, 2011
Last Updated
September 10, 2015
NCT06056102
NCT06297343
NCT07237633
NCT05788276
NCT06577805
NCT06227468
Lead Sponsor
Veloxis Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions